Maternal Plasma Elabela, a Biomarker for the Severity and Kidney Function of Human Preeclampsia

Miaoyan Ma1,†, Yuemin Hou2,†, Jinfang Wu2, Yanhua Qi1,*

1Department of Ultrasound, the Second Affiliated Hospital, Xi’an Jiaotong University, 710004 Xi’an, Shaanxi, China
2Department of Obstetrics and Gynecology, the Second Affiliated Hospital, Xi’an Jiaotong University, 710004 Xi’an, Shaanxi, China
*Correspondence: qylhlf@163.com (Yanhua Qi)
†These authors contributed equally.

Abstract

Background: It reported that serum Elabela level was decreased in preeclampsia patients. However, there is no researcher done the study on the correlations between plasma Elabela and kidney function, blood pressure, blood glucose and lipid in preeclampsia patients. Our objective is determined whether plasma Elabela could be a marker for the severity and kidney function of preeclampsia. Methods: 72 pregnant women were enrolled in this study and divided into healthy group (n = 37), mild preeclampsia group (n = 20) and severe preeclampsia group (n = 15). The level of plasma Elabela was detected using ELISA. Results: Plasma Elabela was reduced in preeclampsia patients compared to healthy group, and severe preeclampsia patients had the lower level of Elabela and poorer kidney function. The level of plasma Elabela was negatively correlated with those of uric acid (UA), creatinine (Cre), cystatin C (CysC), systolic blood pressure (SBP) and diastolic blood pressure (DBP). Conclusions: Lower concentration of plasma Elabela correlated with worse kidney function, and higher blood pressures in preeclampsia patients.

Keywords: biomarker; blood pressure; Elabela; kidney function; preeclampsia

1. Introduction

Elabela, also called Apela/Toddler, was first identified in zebrafish embryos in 2013 [1]. It is expressed in adult heart, blood vessels, stem cell, prostate and kidney [1–4]. Elabela is also a hormone related with pregnancy. It can be secreted by embryos, fetus or placenta, and enter into maternal peripheral blood via the ways of paracrine, endocrine or autocrine [3]. The receptor of Elabela is apelin receptor (APJ). APJ is a G-protein-coupled receptor with seven-transmembrane structure [5]. Elabela/APJ signals involve in heart development, embryonic vasculogenesis/angiogenesis, and early placental development [5], also contribute to embryonic stem cells self-renewing, bone formation, development and homeostasis. Moreover, Elabela can lower blood pressure by relaxing the aorta vessels; inhibit renal remodeling and has anti-renal fibrosis function; alleviate food intake, and regulates water homeostasis [6].

Preeclampsia (PE) is a serious complication of pregnancy, usually happens during late 2nd and 3rd trimester. The main clinical manifestations are hypertension and proteinuria. It is caused by the poor perfusion of placenta [7]. The incidence of preeclampsia is 5–7%, and it occupies nearly 20% of pregnant-related deaths [8,9]. Termination of pregnancy is the most effective treatment of preeclampsia. So, the diagnosis of preeclampsia as early as possible is of vital importance.

The role of Elabela in preeclampsia was recently reported by Ho et al. [3] that Elabela knock-out pregnant mice exhibited preeclampsia-like symptoms, including hypertension and proteinuria. Infusion of exogenous Elabela could normalize hypertension and proteinuria. Elabela was secreted by conceptus and placenta, and might act independently and earlier than the angiogenic factors (sFlt1, Vegf, Plgf) in the pathogenesis of preeclampsia. Moreover, human placenta was also examined. Elabela was primarily expressed in villous cytotrophoblasts and syncytiotrophoblasts of placental tissue, and Elabela could contribute to trophoblast invasion and remodeling spiral artery to prevent the development of preeclampsia during human pregnancy.

Although Elabela expression in human preeclampsia has been reported by some articles, it still remains controversial. Panaitescu et al. [10] reported plasma Elabela concentrations in early-onset preeclampsia patients were lower than those in late-onset preeclampsia patients and no difference with normal pregnant women. However, some researchers reported serum Elabela level was remarkably decreased in preeclampsia patients compared to normal pregnancy. In addition, placental Elabela and its receptor APJ were accordingly down-regulated [11–13]. In umbilical arteries and veins of newborns, Elabela concentration was also decreased [13]. Whereas, Pritchard et al. [14] and Vilkie et al. [15] found the levels of placenta and plasma Elabela in preeclampsia patients had no difference with those of normal pregnant women.
So, in our study, we measured the level of plasma Elabela in healthy controls and mild, severe preeclampsia patients, examined the kidney function of preeclampsia patients, and analyzed the correlations between plasma Elabela and kidney function, blood pressure, blood glucose and lipid, finally determined whether plasma Elabela could be a marker for the severity and kidney function of preeclampsia.

2. Materials and Methods

2.1 Patients and Controls

The study enrolled 35 pregnant women who diagnosed for preeclampsia from May 2019 to October 2019 at the second affiliated hospital, Xi’an Jiaotong University. The inclusion criteria were as follow: (1) Preeclampsia diagnosed and categorized according to ACOG (the American College of Obstetrics and Gynecology) practice bulletin [16]; (2) age ≤35 years; (3) natural conception, single pregnancy, first pregnancy.

37 age-and gestation weeks-matched pregnant volunteers were enrolled to serve as healthy controls. The inclusion criteria: natural conception, single pregnancy, first pregnancy, no systemic disease, no complications during pregnancy, and no tumor disease.

Pregnant women were excluded from the study if they (1) pregnant after in vitro fertilization (IVF), multiple pregnancies, chromosomal abnormalities of pregnant women and fetus, (2) complicated with primary renal system disease, (3) had liver disease, heart failure, stroke, rheumatic disease, autoimmune disease, or malignant tumors, (4) Body Mass Index (BMI) >28.

The study was approved by the ethics committee of the second affiliated hospital, Xi’an Jiaotong University. The study protocol was explained to all patients, and each participant provided written informed consent.

2.1.1 Study Design

According to the inclusion and exclusion criteria, 72 late pregnant women were enrolled in our study. The plasmas were collected from healthy pregnant women, mild and severe preeclampsia patients, and the level of plasma Elabela was detected using enzyme linked immunosorbent assay (ELISA). The sera were examined for kidney functions (blood urea nitrogen (BUN), creatinine (Cre), glomerular filtration rate (GFR), uric acid (UA), cystatin C (CysC)), and also for glucose and lipid metabolism (fasting plasma glucose (FPG), total cholesterol (TCHO), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C)) using biochemical analyzer. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were recorded for every subject. The correlations between plasma Elabela and the above clinical parameters were analyzed.

2.1.2 ELISA Measurement of Elabela

Venous blood samples were collected in Ethylene Diamine Tetraacetic Acid (EDTA) anticoagulation tubes from healthy controls and preeclampsia patients. The blood samples were centrifuged at 3000 rpm/min for 15 min, and the plasmas were stored at –80 °C until use. The level of human Elabela was detected using ELISA kit (Laibio, Shanghai, China) according to manufacturer’s protocol. Each sample was measured in duplicate and the mean was calculated.

2.2 Biochemical Analysis

Venous blood samples were collected in procoagulant tubes from healthy controls and preeclampsia patients, the following parameters: BUN, Cre, GFR, UA, CysC, FPG, TCHO, TG, HDL-C and LDL-C were detected by fully automatic biochemical analyzer (BX-4000, sysmex corporation, Japan). The correlations between the concentration of Elabela and the levels of the above parameters were also analyzed.

2.3 Statistical Analysis

The results are presented as the mean ± standard deviation (SD). Comparisons between groups were performed using the one-way analysis of variance (ANOVA) or the Kruskal-Wallis H test, as appropriate. The relationships between the concentration of plasma Elabela and the levels of other clinical parameters were evaluated using Spearman’s correlation. Linear regression analyses were conducted to confirm the correlation. The above analyses were performed using PRISM software 8.0 (GraphPad software Inc., La Jolla, CA, USA). Statistical significance defined as p < 0.05 (*), p < 0.01 (**), p < 0.001 (***).

3. Results

3.1 Characteristics of the Study Population

A total of 72 women were included in our study. Table 1 showed the clinical characteristics of the enrolled cases. The mean ages of mild (n = 20) and severe (n = 15) preeclampsia patients were 29.41 ± 4.34 and 29.11 ± 3.24 years old, and there were no significant differences between healthy pregnant group (n = 37, age: 31.01 ± 4.12 years old) and preeclampsia groups in the age. The weeks of pregnancy were all after 35 weeks of gestation. Mild and severe preeclampsia patients had higher SBP and DBP compared to healthy controls. Moreover, SBP and DBP of severe preeclampsia group were higher than that of mild group (p < 0.001).

3.2 The Level of Plasma Elabela was Decreased in Preeclampsia Patients and Correlated with the Severity of Preeclampsia

The level of plasma Elabela was decreased in mild (4.146 ± 0.830 ng/mL, p = 0.0182) and severe (3.030 ± 1.007 ng/mL, p < 0.001) preeclampsia patients than healthy controls (5.071 ± 1.401 ng/mL). Moreover, severe
Table 1. Clinical characteristics of healthy controls and preeclampsia patients at late gestation.

| Groups              | Numbers (n) | Ages (y)   | Weeks of pregnancy (w) | SBP (mmHg) | DBP (mmHg) |
|---------------------|-------------|------------|------------------------|------------|------------|
| Healthy pregnant    | 37          | 31.01 ± 4.12| 35±1–38±6              | 119.9 ± 5.120 | 76.73 ± 6.419 |
| Mild preeclampsia   | 20          | 29.41 ± 4.34| 36±3–38±5              | 147.3 ± 5.230** | 100.4 ± 5.706*** |
| Severe preeclampsia | 15          | 29.11 ± 3.24| 35±2–37±1              | 170.0 ± 6.536***,# | 118.3 ± 5.133***,# |

∗∗∗p < 0.0001, compared with healthy pregnant controls.
*p < 0.0001, compared with mild preeclampsia group.
p values were from the one-way analysis of variance (ANOVA).
SBP, systolic blood pressure; DBP, diastolic blood pressure.

Preeclampsia patients had the lowest Elabela level (Fig. 1). So, the decreased level of plasma Elabela was correlated with the severity of preeclampsia.

![Fig. 1. The detection of plasma Elabela levels in mild and severe preeclampsia patients and healthy controls.](image1)

3.3 The Decreased Level of Plasma Elabela was Correlated with the Severity of Kidney Dysfunction in Preeclampsia Patients

Because preeclampsia patients might manifest kidney dysfunction, we then detected the kidney function of mild and severe preeclampsia patients. The levels of UA, Cre and CysC were up-regulated in preeclampsia patients than healthy controls. Among the levels of severe preeclampsia patients were highest. However, GFR was decreased in mild and severe preeclampsia patients than healthy controls (Fig. 2). These results indicated that the more severe symptoms of preeclampsia, the worse function of kidney.

We then analyzed the correlation between the level of plasma Elabela and renal function, blood pressure, glucose and lipid metabolism. The level of plasma Elabela was negatively correlated with those of UA, Cre, CysC, SBP and DBP. However, it was positively correlated with that of GFR. Moreover, there were no correlations between the level of plasma Elabela and BUN, FPG, TCHO, TG, HDL-C, LDL-C (Fig. 3). These results indicated that the lower level of plasma Elabela, the worse function of kidney, thus the more severe symptoms of preeclampsia.

4. Discussion

Since Ho et al. [3] reported Elabela deficiency promoted preeclampsia in mice, several research groups examined the level of Elabela in human preeclampsia, and the results were controversial. The different Elabela levels from different research groups might be due to different samples used (maternal plasma or serum, umbilical artery and vein), or because Elabela is a small peptide hormone which can be quickly degraded by protease, the improper sample collection and preservation might cause disparate results [5]. In our studies, we found that the level of plasma Elabela
was decreased in preeclampsia patients, and the level was lower in severe preeclampsia patients compared to that in mild preeclampsia ones. Our results were in line with Ho et al. [3], Zhou et al. [11], Hao et al. [12] and Deniz et al. [13], indicating that Elabela might provide a protective role in human preeclampsia, the decreased Elabela aggravated the severity of preeclampsia.

The clinical manifestations of preeclampsia patients are arteriole spasm induced increased vascular resistance, and then the reduced organic blood flow. The kidney is the most affected organ. It shows that glomerular spasm, insufficient blood supply, kidney tubules injury, and then the decreased function of kidney, electrolyte and acid-base disturbance, even kidney failure, eventually threat the safety of mother and fetus. Clinically, Cre, UA, CysC and GRF are used to evaluate kidney function [17,18]. In our studies, compared to normal pregnancy, the levels of UA, Cre, CysC were increased, and GFR was decreased in preeclampsia patients, indicating the kidney function was affected in preeclampsia patients. In addition, severe preeclampsia patients had the poorer kidney function than mild preeclampsia patients.

Elabela, highly expressed in the kidney, has been proved to have protective roles on kidney. Chen et al. [19] reported that the level of Elabela was markedly reduced in murine acute kidney injury (AKI). In vitro exper-
imments showed that overexpression of Elabela in cultured renal tubular cells could suppress AKI-induced inflammation, DNA damage and apoptosis. Moreover, Elabela could promote the viability of renal tubular cells. Elabela also suppressed DNA damage response (DDR) in adriamycin-stimulated renal tubular cells. In vivo studies showed that Elabela treatments inhibited AKI-induced morphologic changes, inflammation and fibrosis. A recent study by Lu et al. [20] revealed that in chronic kidney disease patients, serum Elabela levels decreased with decreasing eGFR. In our studies, we found that the level of Elabela was negatively correlated with that of UA, Cre, CysC, and positively correlated with GFR in preeclampsia patients, indicating that human Elabela could be a predictive indicator for kidney function in preeclampsia patients. In addition, human Elabela might be a promising reagent in the protection of kidney function. However, whether Elabela is more specific and sensitive than UA, Cre, CysC and GFR in the prediction of kidney function still needs further exploration.

Elabela, as a new ligand of APJ, also played an important role in the regulation of blood pressure. Elabela could bind to APJ and weaken angiotensin II (AngII) ability of contracting blood vessel via down-regulating the expression of FoxM1 and angiotensin-converting enzyme (ACE), thus decrease the blood pressure [21]. Elabela could also reduce high-salt-diet-induced hypertension in rats [22]. Yang et al. [4] reported that the level of Elabela was markedly decreased in pulmonary arterial hypertension (PAH) patients and rats, exogenous administration of Elabela could attenuate the elevation of right ventricular systolic pressure and myocardial hypertrophy, as well as pulmonary vascular remodeling, thus ameliorated PAH in rats. In our studies, the level of Elabela was reduced, while SBP and DBP were increased in preeclampsia patients, indicating Elabela might also participate in the regulation of blood pressure in the pregnant women.

In addition, Elabela could suppress food intake via activation of anorexigenic neuropeptide arginine vasopressin (AVP) and corticotropin-releasing hormone (CRH) neurons, and increase c-Fos expression and [Ca$^{2+}$] in paradoxic ventricular nuclei (PVN) [6]. Apelin, another ligand for APJ, was expressed on adipose tissues. It was reported that insulin could increase the expression of apelin, while dexamethasone could inhibit the level of apelin [23,24]. So, whether Elabela, sharing the same receptor with apelin, could affect glucose metabolism. In our studies, we did not find the significant correlation between the level of Elabela and FPG. In addition, there were no correlations between Elabela concentration and lipid metabolism.

5. Conclusions

The level of Elabela was decreased and negatively correlated with the severity of preeclampsia. Preeclampsia patients had kidney dysfunction. Decreased level of Elabela was correlated with poorer kidney function in preeclampsia patients. Elabela could be a marker for predicting the severity and kidney function of preeclampsia patients in the future.

Data Availability Statement

The data are available from the corresponding author on reasonable request.

Author Contributions

JFW and YHQ designed and supervised the study. YMH, MYM performed the experiment. YMH, YHQ analyzed the data. YMH and MYM made statistical analysis. YMH and YHQ wrote the manuscript. YHQ, JFW revised the manuscript. All authors read and contributed to the manuscript.

Ethics Approval and Consent to Participate

All subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of the second affiliated hospital, Xi’an Jiaotong University (approval number: 2021214).

Acknowledgment

We would like to express our gratitude to all those who helped us during the writing of this manuscript. Thanks to all the peer reviewers for their opinions and suggestions.

Funding

This research was funded by the Health Commission of Shaanxi province under grant [number 2018D061] and Key R & D projects of Shaanxi Province, grant [number 2021SF-134, 2021SF-001, 2020SF-057].

Conflict of Interest

The authors declare no conflict of interest.

References

[1] Chng S, Ho L, Tian J, Reversade B. ELABELA: a Hormone Essential for Heart Development Signals via the Apelin Receptor. Developmental Cell. 2013; 27: 672–680.
[2] Wang Z, Yu D, Wang M, Wang Q, Kouznetsova J, Yang R, et al. Elabela-Apelin Receptor Signaling Pathway is Functional in Mammalian Systems. Scientific Reports. 2015; 5: 8170.
[3] Ho L, van Dijk M, Chye STJ, Messerschmidt DM, Chng SC, Ong S, et al. ELABELA deficiency promotes preeclampsia and cardiovascular malformations in mice. Science. 2017; 357: 707–713.
[4] Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R, et al. Elabela/Toddler is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of its Expression in Pulmonary Arterial Hypertension. Circulation. 2017; 135: 1160–1173.
[5] Eberlé D, Marousez L, Hanssens S, Knauf C, Breton C, Deruelle P, et al. Elabela and Apelin actions in healthy and pathological
pregnancies. Cytokine and Growth Factor Reviews. 2019; 46: 45–53.

[6] Xu J, Chen L, Jiang Z, Li L. Biological functions of Elabela, a novel endogenous ligand of APJ receptor. Journal of Cellular Physio-iology. 2018; 233: 6472–6482.

[7] Cindrova-Davies T, Sanders DA, Burton GJ, Charnock-Jones DS. Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovascular Research. 2011; 89: 671–679.

[8] Tomimatsu T, Mimura K, Endo M, Kumasawa K, Kimura T. Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction. Hypertension Research. 2017; 40: 305–310.

[9] Oyston CJ, Stanley JL, Baker PN. Potential targets for the treatment of preeclampsia. Expert Opinion on Therapeutic Targets. 2015; 19: 1517–1530.

[10] Panaitescu B, Romero R, Gomez-Lopez N, Pacora P, Erez O, Vadillo-Ortega F, et al. ELABELA plasma concentrations are increased in women with late-onset preeclampsia. The Journal of Maternal-Fetal and Neonatal Medicine. 2020; 33: 5–15.

[11] Zhou L, Sun H, Cheng R, Fan X, Lai S, Deng C. ELABELA, as a potential diagnostic biomarker of preeclampsia, regulates abnormally shallow placentation via APJ. American Journal of Physiology-Endocrinology and Metabolism. 2019; 316: E773–E781.

[12] Hao S, You J, Chen L, Zhao H, Huang Y, Zheng L, et al. Changes in pregnancy-related serum biomarkers early in gestation are associated with later development of preeclampsia. PLoS ONE. 2020; 15: e0230000.

[13] Deniz R, Baykus Y, Ustebay S, Ugur K, Yavuzkir Ş, Aydin S. Evaluation of elabela, apelin and nitric oxide findings in maternal blood of normal pregnant women, pregnant women with pre-eclampsia, severe pre-eclampsia and umbilical arteries and venules of newborns. Journal of Obstetrics and Gynaecology. 2019; 39: 907–912.

[14] Pritchard N, Kaita’u-Lino TJ, Gong S, Dopieralna J, Smith GCS, Charnock-Jones DS, et al. ELABELA/APELA Levels are not Decreased in the Maternal Circulation or Placenta among Women with Preeclampsia. The American Journal of Pathology. 2018; 188: 1749–1753.

[15] Villie P, Lefevre G, Arrester R, Rousseau A, Berkane N, Hettig A. ELABELA concentration is not decreased in maternal plasma before the onset of preeclampsia. American Journal of Obstetrics and Gynecology. 2019; 220: 284–285.

[16] ACOG Committee on Practice Bulletins–Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstetrics and Gynecology. 2002; 99: 159–167.

[17] Kastl JT. Renal function in the fetus and neonate – the creatinine enigma. Seminars in Fetal and Neonatal Medicine. 2017; 22: 83–89.

[18] Niemczyk S, Piotrowska M, Szamotulska K. Usefulness of creatinine and cystatin C in the assessment of renal function in chronic kidney disease and coexisting diseases. Polski Merkuriusz Lekarski. 2012; 32: 313–317. (In Polish)

[19] Chen H, Wang L, Wang W, Cheng C, Zhang Y, Zhou Y, et al. ELABELA and an ELABELA Fragment Protect against AKI. Journal of the American Society of Nephrology. 2017; 28: 2694–2707.

[20] Lu X, Liu S, Luan R, Cui W, Chen Y, Zhang Y, et al. Serum elabela and apelin levels during different stages of chronic kidney disease. Renal Failure. 2020; 42: 667–672.

[21] Sato T, Sato C, Kadowaki A, Watanabe H, Ho L, Ishida J, et al. ELABELA-APELA axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage. Cardiovascular Research. 2017; 113: 760–769.

[22] Schreiber C, Holditch S, Generous A, Ikeda Y. Sustained ELABELA Gene Therapy in High-salt Diet-induced Hypertensive Rats. Current Gene Therapy. 2017; 16: 349–360.

[23] Wei L, Hou X, Tatamoto K. Regulation of apelin mRNA expression by insulin and glucocorticoids in mouse 3T3-L1 adipocytes. Regulatory Peptides. 2005; 132: 27–32.

[24] Boucher J, Masri B, Daviaud D, Gesta S, Guigné C, Mazucotelli A, et al. Apelin, a Newly Identified Adipokine up-Regulated by Insulin and Obesity. Endocrinology. 2005; 146: 1764–1771.